Today’s fungal plant disease control efforts tend towards environmentally friendly and reduced chemical applications. While traditional broad-spectrum fungicides provide efficient protection to many field crops, they pose a risk to the soil’s beneficial microflora and a potential health hazard. Moreover, their intensive use often evokes the appearance of resistant pathogens. On the other hand, biocontrol agents such as Trichoderma spp. provide a green solution but often cannot shield the plants from aggressive disease outbreaks. Integrated biological and chemical disease control can combine the benefits of both methods while reducing their drawbacks. In the current study, such a bio-chemo approach was developed and evaluated for the first time against the maize late wilt pathogen, Magnaporthiopsis maydis. Combinations of four Trichoderma species and Azoxystrobin were tested, starting with an in vitro seed assay, then a growth room sprouts trial, and finally a semi-field, full-season pot experiment. In the plates assay, all four Trichoderma species, Trichoderma sp. O.Y. (T14707), T. longibrachiatum (T7407), T. asperellum (P1) and T. asperelloides (T203), grew (but with some delay) in the presence of Azoxystrobin minimal inhibition concentration (0.005 mg/L). The latter two species provided high protection to sprouts in the growth room and to potted plants throughout a full season in a semi-field open-enclosure trial. At harvest, the P1 and T203 bio-shielding exhibited the best parameters (statistically significant) in plant growth promotion, yield increase and late wilt protection (up to 29% health recovery and 94% pathogen suppression tracked by real-time PCR). When applied alone, the Azoxystrobin treatment provided minor (insignificant) protection. Adding this fungicide to Trichoderma spp. resulted in similar (statistically equal) results to their sole application. Still, the fact that Azoxystrobin is harmless to the beneficial Trichoderma species over a complete semi-field condition is a great opening stage for carrying out follow-up studies validating the integrated control in a commercial field situation challenged with acute disease stress.